Merck & Co. Inc.'s PD-1 inhibitor Keytruda has failed to show a survival benefit in the KEYNOTE-040 study of head and neck cancer, which was meant to confirm an accelerated approval, but the company does not foresee a labeling change.
Merck sais July 24 that median overall survival (OS) for Keytruda in the study of recurrent or metastatic head and neck cancer was better than investigator's choice of chemotherapy, with an 18% reduction in risk for death in the KEYNOTE-040
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?